Home Stock

Stock Research: Hikma Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Hikma Pharmaceuticals

LSE:HIK GB00B0LCW083
82
  • Value
    96
  • Growth
    13
  • Safety
    Safety
    74
  • Combined
    71
  • Sentiment
    69
  • 360° View
    360° View
    82
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Hikma Pharmaceuticals PLC is a pharmaceutical company focused on developing, manufacturing, and marketing generic, branded, and in-licensed pharmaceutical products. The company operates in the pharmaceuticals industry through three segments: Injectables, Branded, and Generics. It operates in the United States, Europe, and the Middle East/North Africa (MENA). In the last fiscal year, the company had a market cap of $5,884 million, profits of $1,448 million, and revenue of $3,156 million, with 9308 employees.

more

ANALYSIS: With an Obermatt 360° View of 82 (better than 82% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Hikma Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Hikma Pharmaceuticals. The consolidated Value Rank has an attractive rank of 96, which means that the share price of Hikma Pharmaceuticals is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 96% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 74. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 69. But the consolidated Growth Rank has a low rank of 13, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 87 of its competitors have better growth. ...read more

more
Strongest Rank Growth
Weakest Rank Value
Country United Kingdom
Industry Pharmaceuticals
Size Large
Website hikma.com
Index
FTSE All Shares
FTSE 100
FTSE 350
Hikma Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 74 81 88
Growth
13 30 41 21
Safety
Safety
74 47 42 53
Sentiment
69 90 90 72
360° View
360° View
82 78 90 68
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
69 45 51 71
Opinions Change
50 56 61 50
Pro Holdings
n/a 67 72 20
Market Pulse
37 95 77 81
Sentiment
69 90 90 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 74 81 88
Growth
13 30 41 21
Safety Safety
74 47 42 53
Combined
71 55 62 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
93 52 67 75
Price vs. Earnings (P/E)
73 63 75 83
Price vs. Book (P/B)
77 42 52 64
Dividend Yield
93 74 76 78
Value
96 74 81 88
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
36 48 10 59
Profit Growth
61 23 65 56
Capital Growth
15 24 25 6
Stock Returns
14 72 76 30
Growth
13 30 41 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
31 41 28 35
Refinancing
94 45 69 60
Liquidity
54 56 38 50
Safety Safety
74 47 42 53

Similar Stocks

Discover high‑ranked alternatives to Hikma Pharmaceuticals and broaden your portfolio horizons.

Costain

LSE:COST
Country: United Kingdom
Industry: Construction & Engineering
Size: Medium
Full Stock Analysis

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

RS Group

LSE:RS1
Country: United Kingdom
Industry: Trading & Distribution
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews